search for




 

Medical Treatment of Graves’ Disease
Int J Thyroidol 2019;12(2):79-84
Published online November 30, 2019;  https://doi.org/10.11106/ijt.2019.12.2.79
© 2019 Korean Thyroid Association.

Hyun-Kyung Chung

Division of Endocrinology, Department of Internal Medicine, Dankook University Hospital, Cheonan, Korea
Correspondence to: Hyun-Kyung Chung, MD, PhD, Division of Endocrinology, Department of Internal Medicine, Dankook University Hospital, 201 Manghyang-ro, Dongnam-gu, Cheonan 31116, Korea
Tel: 82-41-550-3057, Fax: 82-41-556-3256, E-mail: chkendo@dankook.ac.kr
Received October 8, 2019; Revised November 5, 2019; Accepted November 9, 2019.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Among the three treatment modalities of Graves’ disease which include antithyroid drug (ATD), radioactive iodine and surgery, the ATD is most commonly preferred in Korea due to ease of use and definite curative effects on the thyrotoxic symptoms. However, several uncertainties about ATD remain: for example, the mechanism of actions on immune modulation, differences in the effects of drugs among individuals and associated factors in the view of remission. In recent years, long-term ATD treatment has been confirmed as an effective and safe therapy modality in adults, and several treatment guidelines have been released which accept long-term ATD therapy as an acceptable alternative to ablative therapy in Graves’ patients. In this review, we summarize the recent progress in understanding the clinical role of ATD and emerging new antithyroid drugs focusing on immunomodulation.
Keywords : Graves’ disease, Antithyroid drug, Remission


November 2019, 12 (2)